Periprocedural Mortality Risk After Elective Atrial Fibrillation Ablation in Japan

• by Koichi Inoue, Koshiro Kanaoka, Yasunori Ueda, Haruhiko Abe, Kuniyasu Ikeoka, Tsuyoshi Mishima, Tatsuhisa Ozaki, Takuya Ohashi, Satoshi Osaki, Yoko Sumita, Yoshitaka Iwanaga, Yasushi Matsumura, Yasushi Sakata

• August 29, 2026

Association of glucagon-like peptide-1 receptor agonists with atrial fibrillation recurrence after catheter ablation: a systematic review and meta-analysis

• by Dan He, Defu Lv, Jiaxin Tang, Xiaojuan Liao, Ping Mao, Zhu Tian

• August 27, 2026

TOFA may drive weight loss without reducing food intake

The oral compound increased energy expenditure, reduced fat mass, and improved metabolic measures in male mouse models.

• by Andrea Surnit

• August 27, 2026

• 4 min

Tirzepatide’s cardiovascular effects in clinical practice

Investigators compared cardiovascular outcomes with tirzepatide and a placebo proxy in patients with type 2 diabetes and established atherosclerotic cardiovascular disease.

• by Kathryn Wighton

• August 28, 2026

• 4 min